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Cattle bile (CB) has long been used in Japan as an ingredient of digestive medicines. Bile acids are major chemical constituents of
CB,andCBingestionisassumedtoaﬀectsmallintestinalinjuryinducedbynonsteroidalanti-inﬂammatorydrugs (NSAIDs).Mice
were fed a diet supplemented with or without CB for 7 days and treated with diclofenac sodium (DIF) to induce small intestinal
injury. Lesion formation was enhanced, and PGE2 content and COX expression levels were elevated in the small intestine of DIF-
treated mice fed the CB diet compared with those fed the control diet. The administration of a reconstituted mixture of bile acids
found in CB enhanced lesion formation in DIF-treated mice. CB administration elevated the contents of CB-derived bile acids
in the small intestine, some of which exhibited a high cytotoxicity to cultured intestinal epithelial cells. These results suggest that
the elevated levels of CB-derived cytotoxic bile acids in the small intestine contribute to the aggravation of DIF-induced small
intestinal injury. The use of CB may be limited during the therapy of inﬂammatory diseases with NSAIDs.
1.Introduction
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are exten-
sively used as antipyretics and analgesics. However, long-
term ingestion of NSAIDs induces gastrointestinal side
eﬀects, such as lesion formation in the stomach and duode-
num [1]. Inaddition, recent investigations haverevealed that
lesion formation and erosion in the small intestinal mucosa
are induced more frequently than those in the stomach and
duodenum [2]. Intestinal bleeding and anemia due to small
intestinal injury are relevant in rheumatic patients taking
NSAIDs [3–5]. Experimental studies have also conﬁrmed
that the administration of several types of NSAID in rats
and mice can induce mucosal injury predominantly in the
small intestine accompanied by intestinal inﬂammation and
lesion formation associated with severe bleeding and blood
loss [6, 7].
NSAIDs inhibit mucus secretion and increase the
motility of the small intestine through the inhibition of
prostaglandin synthesis by cyclooxygenase-1 (COX-1) [8].
These pathological responses facilitate bacterial transloca-
tion into the intestinal mucosa, which triggers various
immunoinﬂammatory reactions, such as leukocyte inﬁltra-
tion and the generation of reactive oxygen species and
proinﬂammatory cytokines [8]. Bacterial translocation also
upregulates COX-2 expression, leading to the stimulation of
prostaglandin synthesis in the small intestine [8]. However,
this COX-2-dependent prostaglandin synthesis plays a pro-
tective role by attenuating the earlier pathological events
due to the inhibition of COX-1-dependent prostaglandin
synthesis by NSAIDs in the small intestine. However,
NSAIDs also decrease COX-2 activity and thereby induce
small intestinal injury. Thus, the decrease in both COX-1
and COX-2 activities is involved in the mechanism by which
NSAIDs induce small intestinal injury.
Bile acids associated with phospholipids in bile; there-
fore, their hydrophobicity and cytotoxicity for intesti-
nal epithelia are attenuated [9]. However, it is shown
that NSAIDs can liberate free bile acids from bile acid-
phospholipid complexes. The liberated free bile acids are
more potent in injuring intestinal epithelial cells than their
complexes with phospholipids [10]. The ability of NSAIDs
to liberate free bile acids from bile acid-phospholipid
complexes is considered to be due to their ability to bind
to phospholipids [11] or directly to bile acids [12]. In
particular, the cytotoxicity of complexes of NSAIDs and
bile acids is assumed to be extremely high [12]. Thus, the2 Evidence-Based Complementary and Alternative Medicine
interaction of NSAIDs with phospholipids or bile acids
can explain the mechanism by which NSAIDs induce small
intestinal injury depending on the cytotoxicity of bile
acids for intestine epithelial cells. There are several studies
examining the eﬀects of administration of bile acids on
NSAID-induced small intestinal injury in the experimental
animals. Oral administration of taurochenodeoxycholic acid
ameliorated, but that of ursodeoxycholic acid exacerbated,
small intestinal injury in indomethacin-treated rats [13]. In
contrast, ursodeoxycholic acid could ameliorate ibuprofen-
induced small intestine injury in rats [14]. Since taurochen-
odeoxycholate is a hydrophobic, but ursodeoxycholic acid
is a relatively less hydrophobic bile acid, the eﬀects of
bile acids with diﬀerent hydrophobicity on NSAID-induced
small intestinal injury in the experimental animals were not
simply reﬂected by physiochemical properties of bile acids.
Animal bilepreparations harvestedfrom diﬀerentanimal
species, such as bear, cattle, and pig, have long been
used, mainly in Asian countries. In particular, animal bile
preparations are used as ingredients of digestive medicines
in Japan. Bile acids are the major chemical constituents of
animal bile preparations and facilitate the emulsiﬁcation and
hydrolysis of dietary fats by pancreatic lipases [15]. These
properties explain the usefulness of animal bile preparations
as an ingredient of digestive medicines. However, ingested
bile acids are incorporated into the enterohepatic circulation
and change the bile acid composition in bile and the
small intestinal lumen [16, 17]. Therefore, the ingestion of
hydrophobic bile acids might increase the hydrophobicity of
the bile acids in bile or the small intestinal lumen. Among
the animal bile preparations used in Japan, cattle bile (CB) is
mostextensivelyusedasaningredientofdigestivemedicines,
but it is constituted of bile acids with a relatively high
hydrophobicity, such as taurine and glycine conjugates of
cholic and deoxycholic acids [15]. Thus, the ingestion of CB
is suggested to elevate the levels of hydrophobic bile acids in
bile and the small intestinal lumen. However, no study has
exactly tested the eﬀect of the administration of cattle bile as
well as bile acids contained in this animal bile on NSAID-
induced small intestinal injury. Therefore, it is necessary
to clarify whether NSAID-induced small intestinal injury is
aggravated by the administration of CB.
In this study, we examined the eﬀe c to fC Ba d m i n i s t r a -
tion on small intestinal injury induced by diclofenac sodium
(DIF),themostextensivelyusedNSAIDinhospitals,inmice.
Lesion formation, COX expression levels, and prostaglandin
contentinthesmall intestinewereassessed asindicesofsmall
intestinal injury [8]. Furthermore, we investigated the role of
bile acids in the modulation of DIF-induced small intestinal
injury byCBadministration byevaluatingthechangesinbile
acid composition in the small intestine and the cytotoxicity
of the bile acids found in the small intestine of mice for
intestinal epithelial cells in vitro.
2.Materialsand Methods
2.1. Animal Treatments. Male ddY mice (SLC, Shizuoka,
Japan) at 5 weeks of age were acclimated in the environment
Table 1: Bile acid composition of cattle bile.
Bile acids Proportion (%, w/w)
Taurocholic acid (TCA) 19.5
Glycocholic acid (GCA) 14.0
Glycodeoxycholic acid (GDCA) 1.7
Taurodeoxycholic acid (TDCA) 4.9
of our animal room for 1 week before the treatments were
started. CB used in this study was obtained as a semidry
paste (Mitsuhoshi Pharmaceutical Co., Nara, Japan, Lot.
A-007). Bile acid composition in CB was determined by
high-performance liquid chromatography (HPLC; LC-10A,
Shimadzu Co. Ltd., Kyoto, Japan) coupled with the use
of an evaporative light-scattering detector (ELSD; Sedex
75, SEDERE, Alfortville, France) as described previously
[18]; the composition is shown in Table 1. A powdered
diet (CE-2, Clea, Tokyo, Japan) was used to prepare the
control and CB-supplemented diets. CB was added to the
basal diet at 0.2% (w/w), and mice were fed the test
diet for 7 days. A nonsupplemented diet was used as the
control diet. In the experiment to examine the eﬀect of the
reconstituted mixture of the bile acids found in CB, the
basal diet was supplemented with a mixture of taurocholic
acid (TCA), glycocholic acid (GCA), taurodeoxycholic acid
(TDCA), and glycodeoxycholic acid (GDCA) at 39, 28, 3.4
and 9.8mg/100g diet, respectively, which were based on the
proportions of these bile acids in CB (Table 1). These bile
acids were purchased from Steraloids Inc. (Newport, RI).
After the mice were fed the control and test diets for 7 days,
DIF (Wako Pure Chem, Osaka, Japan) dissolved in distilled
water was orally administered to the mice at 20mg/kg body
weight, and, thereafter, the same diets were administered
for an additional 24 hours [19]. Mice fed the control diet
were orally administered with only distilled water as the
untreated control group. The protocols for this experiment
were approved by the Committee for Animal Care and
Experiments of the University of Toyama.
2.2. Assessment of Small Intestinal Lesion Formation. Mice
were killed 24 hours after DIF administration by cervical
dislocation under anesthesia with gaseous isoﬂurane (5%
w/v in air), and the entire small intestine was harvested.
Immediately, the small intestine was excised along antime-
senteric lines and ﬂattened on a dry ﬁlter paper. The small
intestine was covered with another piece of ﬁlter paper and
immersed into 10% formalin overnight to ﬁx the tissues.
The number and the sum of length of lesions in the small
intestinal mucosa were determined under a stereoscope as
described previously [19]. Measurement was performed by
an observer who was blind to the treatments of sample
specimens.
2.3. Determination of Contents of Bile Acids and Prostaglandin
E2 in Small Intestine. Entire small intestines were harvested
from the mice 24 hours after DIF administration and
homogenized in 10mL of 99.5% ethanol using TeﬂonEvidence-Based Complementary and Alternative Medicine 3
potter homogenizers. The homogenates were centrifuged
at 3000rpm for 10 minutes, and the resultant super-
natants were used for the determination of bile acid and
prostaglandin E2 (PGE2) contents. Bile acids were extracted
from an aliquot of ethanol extracts using octadecylsilyl-
bondedsilica cartridges (Sep-Pak C18,Waters, Milford, MA)
as described previously [20]. Bile acid-containing fractions
eluted from the cartridge were dried under nitrogen gas
and dissolved in aliquots of the mobile phase used for
HPLC. Details of the procedures for the determination of
bile acids by HPLC were reported previously [16]. For the
determination of PGE2 content, ethanol extracts from the
small intestine prepared as described above were dried under
nitrogen gas. PGE2 content in the samples was determined
using enzyme immunoassay kits (Cayman Chemicals, Ann
Arbor, MI) [21].
2.4. Western Blot Analysis of Cyclooxygenase Isoforms in Small
Intestine. As described above, mice fed the control or CB
diet for 7 days were treated with DIF or vehicle, and the
small intestine was harvested. The small intestine was excised
and washed in cold saline to remove luminal contents. The
specimens were blotted onto dry ﬁlter papers to remove
excess water. The expression levels of COX-1 and COX-2 in
the small intestine were determined by western blot analysis
as described previously [21].
2.5. Cytotoxicity of Bile Acids to Cultured Intestinal Epithelial
Cells. The cytotoxicity of bile acids were compared using
a cultured rat intestinal epithelial cell line, IEC-18 (DS
Pharma Biomedical, Osaka, Japan) [22]. The cells growing
in Dulbecco’s minimum essential medium (MEM; Wako
Pure Chem., Osaka, Japan) supplemented with 10% (v/v)
fetal bovine serum and 5µg/mL insulin (Sigma-Aldrich, St.
Louis, MO) under humidiﬁed air containing 5% CO2 were
suspended in the same medium and treated with trypsin.
The cells were divided into the wells of microplates at 2.5
× 104 cells/well and incubated for 24 hours. Bile acids
dissolved in the culture medium were added to the wells
of microplates at ﬁnal concentrations of 2 and 4mg/mL
in triplicate. The cells were further incubated for 24 hours
and nonadhering cells were removed by washing with
calcium- and magnesium-free phosphate-buﬀered saline
(PBS) twice. Adhering cells were treated with 0.5% crystal
violet(w/v)containing 20%methanol for 10 minutes. Excess
dye was washed by immersing the plates in tap water. After
the plates were dried, 1% (w/v) sodium dodecyl sulfate
(SDS) was added (100microL/well), and the absorbance at
595nm was measured using a microplate reader (Multiscan
FC, Thermo Scientiﬁc, Vantaa, Finland). Cell viability was
expressed as the percentage of absorbance of the cells
treated with bile acids with respect to that of the untreated
cells.
2.6. Statistical Analysis. The statistical signiﬁcance of the
diﬀerence between the control- and CB-diet-fed groups was
e s t i m a t e db yu n p a i r e dS t u d e n t ’ st-test. For the analysis of the
eﬀects of DIF treatment and CB administration and their
L: 3,389.936
Figure 1: Typical imageoflesionedsmallintestinalmucosaof DIF-
treated mice. Arrows indicate the lesions formed along the line
of mesenteric attachment of the small intestine. The dotted line
indicates the length of the ulcers.
interaction,two-wayanalysisofvariance(ANOVA)wasused.
Probability values below 0.05 are considered statistically
signiﬁcant.
3.Results
3.1. CB Aggravates DIF-Induced Lesion Formation in Small
Intestine. A typical feature of small intestinal lesions of DIF-
treated mice is shown in Figure 1. Lesions were formed along
the lines of the mesenteric attachment of the small intestine
of DIF-treated mice. The number of lesions formed in the
small intestine of DIF-treated mice was signiﬁcantly greater
in the mice fed a diet supplemented with CB at 0.2% (w/w)
thaninthecontrolgroup(P<. 01;Figure 2).Thetotallength
of lesions tended to be greater in the CB group than in the
control group (.05 <P<. 1).
3.2. CB Increased COX Expression Levels and PGE2 Content
in Small Intestine of DIF-Treated Mice. COX-2 was unde-
tectable in the small intestine from untreated mice, but was
detectable in that from DIF-treated mice (Figure 3(a)). The
administration of CB only did not induce the elevation of
COX-2 in the small intestine of mice. However, combined
treatments with CB and DIF markedly elevated the COX-2
expression level in the small intestine. In contrast, COX-1
was detectable even in the small intestine of untreated mice
but its level tended to be elevated in the small intestine of
mice treated with DIF or CB. In addition, the combined
treatment with CB and DIF elevated the expression level
of COX-1 in the small intestine. Although DIF treatment
did not signiﬁcantly change the PGE2 content in the small
intestine, CB administration exerted signiﬁcant eﬀects on
PGE2 content in the small intestine (two-way ANOVA, P<
.001;Figure 3(b)).PGE2 contentinthesmallintestine tended
to be elevated by the interaction between CB and DIF
treatments (two-way ANOVA, .05 <P<. 1).4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Eﬀect of CB administration on the number (a) and length (b) of lesions formed in small intestine of DIF-treated mice. Mice
were fed the control and CB diets, and lesion formation was estimated 24 hours after the oral administration of DIF. Columns and bars,
respectively, represent the mean and SEM from six mice in each group. Statistical analysis was carried out by an unpaired Student’s t-test.
3.3. Reconstituted Mixture of CB-Derived Bile Acids Enhances
Small Intestinal Lesion Formation Induced by DIF. Mice
were fed a diet supplemented with a reconstituted bile acid
mixture composed of TCA, GCA, GDCA, and TDCA at
concentration found in 0.2% CB diet for 7 days, and lesion
f o r m a t i o ni nt h es m a l li n t e s t i n eo fm i c et r e a t e dw i t hD I F
was compared with that of the mice fed the control diet
(Figure 4). It was shown that the number of lesions in the
small intestine of mice fed a diet supplemented with the bile
acid mixture was signiﬁcantly greater than that of mice fed
the control diet (P<. 05). The total length of lesions formed
in the small intestine was slightly greater in the group fed the
reconstitutedbileacid mixturethaninthecontrol group,but
this diﬀerence did not reach statistical signiﬁcance (P = .20).
3.4.Bile AcidCompositioninSmall Intestine. Thesmall intes-
tine of untreated mice contained mainly tauromuricholic
acid (TMCA) and TCA (Figure 5). In two-way ANOVA, CB
administration (P<. 001) but not DIF treatment (P>. 05)
signiﬁcantly changed the contents of TMCA in the small
intestine, although these treatments did not show signiﬁcant
interaction in changing TMCA content (P>. 05). CB
administration signiﬁcantly elevatedTCAcontent(P<. 001)
whereas DIF treatment reduced TCA content (P<. 02) in
the small intestine. However, the interaction between these
treatments was not signiﬁcant (P = .435). GCA and TDCA
as well as CA were detectable in the small intestine of mice
fedthe CBdiet,althoughthecontents ofthese bileacids were
not signiﬁcantly changed by DIF treatment.
3.5. Cytotoxicity of Bile Acids to Cultured Intestinal Epithelial
Cells. The intestinal epithelial cell line IEC-18 was used
to estimate the cytotoxicity of bile acids found in the
small intestine of mice fed the CB diet (Figure 6). Similar
cytotoxicity was shown by TCA and GCA. The cytotoxicity
of TMCA and TDCA were much greater than those of TCA
and GCA, although CA exerted a moderate cytotoxicity.
4.Discussion
The COX-2 expression level was higher in the small intestine
of mice treated only with DIF than in that of untreated mice
(Figure 3(a)). In addition, the COX-1 expression level was
slightly elevated in the small intestine of DIF-treated mice
(Figure 3(a)). The elevation of COX-1 levels is supposed to
be due to its expression in inﬂammatory cells or ﬁbrob-
lasts massively inﬁltrated into the inﬂamed small intestinal
lesions 24 hours after the administration of DIF, (Figure 1).
However,theseresponseswerenotassociatedwithsigniﬁcant
changes in PGE2 content in the small intestine (Figure 3(b)).
These ﬁndings indicate that small intestinal injury induced
by DIF is associated with inﬂammatory responses, although
the upregulation of COX-1 and COX-2 expressions in the
small intestine seems to be insuﬃcient to elicit prostaglandin
generation. In contrast, the small intestine of mice admin-
istered with only CB exhibited a signiﬁcant increase in
PGE2 content despite the absence of signiﬁcant elevation of
COX-2 expression level and only a small elevation of COX-
1 expression level. These ﬁndings suggest that CB could
upregulate PGE2 synthesizing ability mainly owing to the
augmentation of availability of arachidonic acid for PGE2
synthesis. In addition, another possibility of the activation
of PGE synthases might be due to the upregulation of PGE
synthases (PGES) in the small intestine of mice administered
with CB. Furthermore, it should be noted that the combined
treatment with DIF and CB resulted in a robust increase in
PGE2 content in the small intestine, which was accompanied
by the elevation of COX-1 and COX-2 expression levels.
These ﬁndings reﬂect the fact that immunoinﬂammatory
reactions in the small intestine are enhanced as a result ofEvidence-Based Complementary and Alternative Medicine 5
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Figure 3:Eﬀects ofDIF treatment andCBadministrationonCOX-
1 and COX-2 expression levels and PGE2 content in small intestine.
Mice fed the control or CB diet were treated with DIF or vehicle,
and the expression levels of COX-1 and COX-2 (a) and PGE2
content (b) in the small intestine were determined by Western blot
analysis and enzyme immunoassay, respectively. Three and 6 mice
in each group were used for the determination of COX expression
levels and PGE2 content in the small intestine, respectively. Fold
diﬀerence in densitometric values of COX-1 bands compared with
that of untreated group were 2.9, 3.0, and 5.7 in the CB-, DIF-,
and CB/DIF-treated groups, respectively. PGE2 contents in the
small intestine is expressed as mean + SEM. The probability values
estimated in two-way analysis of variance were 0.0634, 0.0004, and
0.0634fortheeﬀectsofDIFtreatment,CBadministration,andtheir
interaction, respectively.
the aggravation of small intestinal lesion formation through
thesynergismbetweenDIFtreatmentandCBadministration
(Figure 2).Thus,PGE2 contentsinthesmall intestineofDIF-
treated mice was enhanced by CB administration, indicating
that the aggravation of DIF-induced small intestinal injury
by CB administration is not due, at the very least, to the
inhibition of COX-mediated prostaglandin generation at 24
hours after DIF administration. However, there might be
a case that CB administration could inhibit COX-mediated
prostaglandin synthesis earlier than this time point. Eﬀect
of CB administration on the time-course changes in PGE2
contents during DIF-induced small intestinal injury should
be further examined.
It can be concluded that bile acids contained in CB
play a crucial role in the aggravation of small intestinal
injury by CB administration in DIF-treated mice because
the administration of a reconstituted mixture of bile acids
found in CB also aggravated small intestinal injury in DIF-
treated mice (Figure 4).However,the augmentationoflesion
formation induced by the reconstituted mixture of bile acids
was slightly lower than that induced by CB administration
(Figure 2). This suggests that factor(s) other than bile acids
could contribute, in part, to the aggravation of DIF-induced
small intestinal injury. UponCBadministration, onlya small
but signiﬁcant elevation of the contents GCA, TDCA, and
CA, whose cytotoxicity to intestinal epithelial cells were
extremely higher than those of endogenous bile acids in
the small intestine (Figure 5), was observed. We, therefore,
suggest that the incorporation of bile acids with higher
hydrophobicity or cytotoxicity from CB into the small
intestinal lumen is involved in the enhancement of small
intestinal injury. On the other hand, the level of TMCA,
the most abundant bile acid in the small intestine of mice,
was reduced, but that of TCA was elevated in the mice
fed the CB diet compared with those fed the control diet
(Figure 5) .B e c a u s eT M C Ai sr e p o r t e dt ob eam u c hl e s s
hydrophobic bile acid [23], its cytotoxicity for IEC-18 cells
was expected to be low. However, the cytotoxicity of TMCA
was rather higher than those of bile acids with relatively
h i g hh y d r o p h o b i c i t y ,s u c ha sT C A ,G C A ,o rC A( Figure 6).
In addition, cytotoxicity of TMCA seemed to be similar to
that of more hydrophobic TDCA, although more detailed
comparison should be made for cytotoxicity of TMCA and
TDCA in their lower concentration ranges. It has also been
reported that the hydrophobicity of bile acids is not the only
determinant of their cytotoxicity, as shown by in vitro tests
[24]. There are possibilities that the cytotoxicity of TMCA
depends on the types of cells or the culture conditions,
such as concentration of serum. The role of the decrease in
TMCA content in the small intestine in the enhancement of
DIF-induced intestinal injury should be further investigated.
However, cytotoxicity of bile acids for cultured intestinal
epithelial cells was examined in the absence of DIF. It is
known that bile acid cytotoxicity for epithelial cells can be
augmented in the presence of NSAID [10]. Therefore, we
should be more careful for the interpretation of cytotoxicity
of diﬀerent types of bile acids in vitro in considering the
role of luminal bile acids in NSAID-induced small intestinal
injury.
Interestingly, TCA was the only bile acid whose level in
the small intestine was reduced in the DIF-treated groups
(Figure 5), suggesting that TCA metabolism is selectively
altered during DIF-induced small intestine injury. Changes
in the rate of secretion of TCA into the intestinal lumen,
deconjugation of TCA in the small intestine, or the absorp-
tion of TCA from the small intestine might be involved
in the decrease in the level of TCA in the small intestine
of DIF-treated mice. In addition, these factors determining
the level of TCA in the small intestine might be directly
aﬀected by DIF. Eﬀects of CB on the expression levels as
well as the activities of transporters ormetabolizing enzymes
for bile acids in the small intestine or liver could elucidate
the selective modulation of TCA level in the small intestine
during DIF-induced small intestinal injury. In addition, we
found that occurrence of unconjugated bile acid, cholic
acid (CA) in the small intestines of mice administered with6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Eﬀect of reconstituted mixture of bile acids contained in CB on number (a) and length (b) of lesions formed in small intestine
of DIF-treated mice. Mice were fed the control diet and the diets supplemented with a mixture of bile acids contained in CB (Table 1), and
lesion formation was estimated 24 hours after the oral administration of DIF. Columns and bars respectively represent the mean and SEM
from six mice in each group. Statistical analysis was carried out by unpaired Student’s t-test.
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Figure 5: Eﬀect of CB administration on contents of bile acids in
small intestine. Mice fed the control or CB diet were treated with
DIF or vehicle and the contents of bile acids in the small intestine
were determined by HPLC. Columns and bars represent the mean
andSEMof3to6miceineachgroup.Statisticalanalysiswascarried
out by two-way ANOVA. CB treatment signiﬁcantly changed both
TMCA and TCA contents in the small intestine (two-way ANOVA,
P<. 0001). DIF treatment signiﬁcantly changed TCA content
(P<. 02) but not TMCA (P>. 05) content in the small intestine.
Interaction between DIF treatment and CB administration was not
signiﬁcant (P>. 05) in terms of both TMCA and TCA contents in
the small intestine.
CB. This form of bile acid is suggested to be generated
in the small intestinal lumen by deconjugation of TCA or
GCA and can be assumed to play a role in the aggravation
of small intestinal injury induced by DIF due to its high
hydrophobicity. However, we have determined bile acid
proﬁles in the small intestinal contents but not in bile.
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Figure 6: Cytotoxicity of bile acids for cultured intestinal epithelial
IEC-18 cells in vitro. IEC-18 cells were treated for 24 hours with the
bile acids found in the small intestine of mice administered with
CB. The viability of treated cells was expressed as the percentage of
absorbance of the cells treated with bile acids with respect to that of
the untreated cells.Columnsandbars represent themeanandSEM,
respectively.
Therefore, it is diﬃcult to predict whether the changes in
TCA and CA levels in the small intestinal contents by the
administration of CB and DIF (Figure 5)o c c u r r e di nl i v e r
or small intestinal lumen. The determination of bile acid
proﬁles in bile or liver would enable us to understand how
CB or DIF administration induced the changes in the levels
of bile acids in the small intestinal contents.
We cannot exclude the possibility that CB-derived bile
acids enhance small intestinal injury independently of the
changes in the cytotoxicityof bileacids in the small intestine.
Infact,conﬂictingresultshavebeenreportedontheeﬀectsof
bile acids with diﬀerent hydrophobicity on NSAID-induced
small intestinal injury in the rats [13, 14]. It has alreadyEvidence-Based Complementary and Alternative Medicine 7
been shown that excretion of NSAIDs into bile is critical to
the development of small intestinal injury; bile duct ligation
can attenuate the secretion of NSAIDs into bile, which is
associated with the attenuation of small intestinal injury in
experimental animals [25, 26]. In addition, the ingestion of
CB might change the absorption, distribution, metabolism,
and elimination of DIF. Bile acids aﬀect the expressions of
metabolizing enzymes and transporters responsible for the
behaviorofDIF[27].Wecansuppose thatformsofbileacids
(conjugated versus unconjugated) or the types of NSAIDs
(indomethacin versus ibuprofen) might be related to the
above conﬂicting results. The diﬀerent chemical forms of
bile acids might exert diﬀerential interaction with diﬀerent
types of NSAIDs in their enterohepatic circulation systems.
Since DIF is known to undergo enterohepatic circulation
[28], it is also possible that DIF interacts with bile acids in
the metabolic processes during this system. We have already
conﬁrmed that the levels of blood DIF following its oral
administration were not modiﬁed in themice fed theCBdiet
compared with those fed the control diet (data not shown).
However,we have notdetermined thelevelsofmetabolitesof
DIF in blood and in enterohepatic circulation. In particular,
the levelsofDIF and itsmetabolites, such as glucuronide,are
importantindeterminingtheextentofsmallintestinal injury
[29]. Further detailed studies are necessary to elucidate the
eﬀect of CB on small intestinal damage from the viewpoint
of the levels of DIF and its metabolites.
InJapan, therangeofdosagesofCBusedasaningredient
in regular digestive medicines is from 50 to 100mg/day.
However, the maximal allowance of daily intake of CB
as an ingredient of digestive medicines is 500mg, which
contains approximately 170mg of cholate and 33mg of
deoxycholate (Table 1). Epidemiological studies would be
helpful to estimate the harmfulness of intake of CB and
NSAID in combination, although no such study has been
carried out. However, a study on humans [16]h a ss h o w n
that the ingestion of cholate at 15mg/kg body weight/day,
approximately 900mg/day when the average body weight is
assumed to be 60kg, for 14 days results in approximately
two-fold higher levels of cholate in the aspirates from the
small intestine than those measured before the treatment.
This change is close to that induced in the small intestine
of mice fed the diet supplemented with 0.2% CB (Figure 6).
Therefore, ingestion of cholate at a regular dosage (50 to
100mg/day) as well as CB even at the maximum dosage
(500mg/day) would cause only smaller changes in the
intestinal bile acid composition than the above-mentioned
condition reported by Woollett et al. [16]. Instead, cholate
dosage as in the above-mentioned human study may cause
harmful eﬀects when taken in combination with NSAIDs.
Since only a single dosage of CB (0.2%) was tested for DIF-
induced small intestinal injury in the present study, it is still
unclear to what extent of aggravation of DIF-induced small
intestinal injury could be induced by the administration of
lower dosages of CB. An approach is also required to clarify
the correlation between the changes in bile acid composition
in the small intestinal lumen and severity of small intestinal
injury in the experimental animals. We should further
investigate to elucidate the mechanism by which cattle
bile aggravates DIF-induced small intestinal injury from
viewpoints of the modiﬁcation of hydrophobicity of bile
acids in the small intestines and of metabolic interaction
between bile acids and DIF in enterohepatic circulation
systems.
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